Servier Pharmaceuticals
Servier Pharmaceuticals
200 Pier Four Blvd,
Boston, MA 02210
Website: https://servier.us/Careers: servier.com/en/careers
Latest news
- FDA Approves Voranigo (vorasidenib) for the Treatment of Grade 2 IDH-Mutant Glioma
6 August 2024 - FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
20 February 2024 - New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib's Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
18 November 2023 - Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
4 June 2023
Drugs Associated with Servier Pharmaceuticals
Servier Pharmaceuticals manufactures, markets and/or distributes more than 5 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Asparlas
Generic name: calaspargase pegol Drug class: miscellaneous antineoplastics |
||
|
Idhifa
Generic name: enasidenib Drug class: miscellaneous antineoplastics |
||
|
Oncaspar
Generic name: pegaspargase Drug class: miscellaneous antineoplastics |
||
|
Tibsovo
Generic name: ivosidenib Drug class: miscellaneous antineoplastics |
||
|
Voranigo
Generic name: vorasidenib Drug class: miscellaneous antineoplastics |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||